The role of RNA modifications in the pathological mechanisms and therapeutic targeting of multiple myeloma

This review examines how epitranscriptomic dysregulation drives multiple myeloma progression, bone destruction, and drug resistance. It explores how RNA-modifying enzymes like METTL3 and FTO regulate disease-relevant transcripts, immune escape, and bone marrow remodeling via exosomes. Targeting these writers and erasers offers promising therapeutic avenues, while RNA modification signatures enable precise risk stratification for effective clinical management.